KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBT: 2009-2025

Historic EBT for Idexx Laboratories (IDXX) over the last 17 years, with Sep 2025 value amounting to $344.8 million.

  • Idexx Laboratories' EBT rose 15.34% to $344.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 16.51%. This contributed to the annual value of $1.1 billion for FY2024, which is 4.59% up from last year.
  • Per Idexx Laboratories' latest filing, its EBT stood at $344.8 million for Q3 2025, which was down 4.85% from $362.4 million recorded in Q2 2025.
  • Idexx Laboratories' EBT's 5-year high stood at $362.4 million during Q2 2025, with a 5-year trough of $171.1 million in Q2 2022.
  • Over the past 3 years, Idexx Laboratories' median EBT value was $285.9 million (recorded in 2023), while the average stood at $289.8 million.
  • Per our database at Business Quant, Idexx Laboratories' EBT soared by 75.54% in 2021 and then plummeted by 32.04% in 2022.
  • Idexx Laboratories' EBT (Quarterly) stood at $191.9 million in 2021, then grew by 11.12% to $213.2 million in 2022, then rose by 12.41% to $239.7 million in 2023, then grew by 6.98% to $256.4 million in 2024, then climbed by 15.34% to $344.8 million in 2025.
  • Its EBT stands at $344.8 million for Q3 2025, versus $362.4 million for Q2 2025 and $310.1 million for Q1 2025.